Loading people...
Holger Reithinger is a General Partner at Forbion, a leading European venture capital firm specializing in life sciences investments. He focuses on identifying and supporting innovative biotech and pharmaceutical companies.
Holger Reithinger invests in innovative biotech and pharmaceutical companies, spanning early-stage to growth-stage opportunities. His focus areas include novel therapeutic solutions across various disease indications, platform technologies, and drug discovery initiatives.
Holger Reithinger works as a General Partner at Forbion, a prominent European life sciences venture capital firm known for its strategic investments in the biotech and pharmaceutical sectors.
Holger Reithinger is a Senior Advisor at the venture capital firm Forbion, based in Munich, Germany. Prior to assuming his current role in April 2025, he served as a General Partner at the firm for 15 years, establishing its Munich office in 2010. Before this tenure, he worked as a Partner at Global Life Science Ventures and an Investment Manager at 3i Group. With over 20 years of investment experience, he has guided numerous biotechnology companies toward successful exits, including the acquisition of Rigontec by MSD and the initial public offering of InflaRx. He also serves on the investment committee of High-Tech Gründerfonds and co-leads the Tax and Finance working group at BIO Deutschland. Reithinger leverages his PhD in biochemistry to focus on funding and building European life sciences, biopharma, and medical device companies.
Holger Reithinger stands as a pivotal figure in the European life sciences venture capital landscape, serving as a General Partner at Forbion. Forbion is renowned for its strategic investments in groundbreaking biotech and pharmaceutical companies, and Holger plays a crucial role in driving this mission forward. His work involves identifying promising early-stage and growth-stage companies with the potential to develop novel therapies and significantly impact patient outcomes.
As a General Partner, Holger Reithinger is deeply involved in all facets of the investment process. This includes rigorous due diligence, deal structuring, and providing strategic oversight to portfolio companies. He leverages his profound understanding of drug discovery, clinical development, and commercialization to guide entrepreneurs and management teams, helping them navigate the complex journey from scientific innovation to market success. His investment philosophy centers on backing companies with strong scientific foundations, clear unmet medical needs, and robust intellectual property.
Holger's investment focus areas are primarily within the biotech and pharmaceutical sectors, encompassing a broad range of therapeutic areas such as oncology, immunology, rare diseases, and neuroscience. He is particularly interested in platform technologies that can generate multiple drug candidates, as well as novel modalities that push the boundaries of medical science. His contributions are instrumental in shaping Forbion's portfolio, ensuring it comprises companies that are not only financially promising but also poised to deliver transformative medical solutions.
Prior to his role at Forbion, Holger Reithinger built a distinguished career marked by significant experience across various facets of the life sciences industry. While specific details of his early career are not publicly detailed, professionals in his position typically bring a rich background from scientific research, pharmaceutical R&D, business development, or corporate strategy roles within leading biotech or large pharmaceutical companies. This diverse experience equips him with a unique perspective, allowing him to bridge the gap between scientific innovation and commercial viability. His career trajectory reflects a deep commitment to advancing healthcare through strategic investment and fostering innovation.
Holger's impact extends beyond capital injection; he often serves on the boards of portfolio companies, providing invaluable guidance on corporate strategy, clinical development pathways, and fundraising. His leadership helps these companies achieve critical milestones, from successful clinical trials to strategic partnerships and exits. Through his dedicated efforts, Holger Reithinger continues to contribute significantly to the growth and success of the European life sciences ecosystem, fostering the development of therapies that address some of the world's most pressing health challenges.
